Miruvor
Sign up
The short answer

What studies of Gabapentin (Neurontin) found

7papers on Gabapentin (Neurontin)
19people in 2 studies testing Gabapentin (Neurontin) alone
1randomised trial, the strongest kind of study

At a glance, by condition

Long COVID: C Might help, very uncertain

Based on the strongest evidence, the randomised trial and studies with no comparison group (very low certainty): 2 of 3 findings are C.

3 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Gabapentin (Neurontin) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 7 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. Gabapentin (Neurontin) · Long COVID is hereC
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. D
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Long COVID

Symptoms

Sleep1 study · 1 (few people) person took Gabapentin (Neurontin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 200mg, at bedtime (few people)

Sleep improved.

The evidence is very uncertain about the effect of gabapentin (Neurontin) on sleep in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. 1171 Hypersomnia Secondary to Long Covid (2024)

    People in the study
    1 in the study
    Dose
    200mg, at bedtime
    Outcome
    sleep inertia
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Smell and taste loss1 study · 18 people took Gabapentin (Neurontin) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 44 people found no clear difference; a small benefit can't be ruled out.

The randomised trial68 randomised · 44 analysed · up to 18 weeks · maximum dose 3600 mg/d, up to 4-week titration; week 1 900 mg/d, week 2 1800 mg/d, week 3 2700 mg/d, week 4 3600 mg/d

No clear difference in smell and taste loss.

The evidence is very uncertain about the effect of gabapentin (Neurontin) on smell and taste loss in long COVID. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 44 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. Efficacy of Gabapentin For Post-COVID-19 Olfactory Dysfunction: The GRACE Randomized Clinical Trial. (2023)

    People in the study
    68 randomised · 44 analysed
    Dose
    maximum dose 3600 mg/d, up to 4-week titration; week 1 900 mg/d, week 2 1800 mg/d, week 3 2700 mg/d, week 4 3600 mg/d
    Outcome
    ODOR scores by mixed-model analysis Olfactory Dysfunction Outcome Rating (ODOR)
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Some concerns
    Missing outcome data
    High
    Measurement of the outcome
    High
    Selection of the reported result
    Some concerns

Daily life and health overall

Daily functioning1 study · 1 (few people) person took Gabapentin (Neurontin) Improvement C
Very low certainty

Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.

Studies with no comparison group1 in the study · 200mg, at bedtime (few people)

Daily functioning improved.

The evidence is very uncertain about the effect of gabapentin (Neurontin) on daily functioning in long COVID. Improvement · very low certainty C

  • No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
  • Few people (1 in all)
  • Not all results were tested against chance
See the 1 study
  1. 1171 Hypersomnia Secondary to Long Covid (2024)

    People in the study
    1 in the study
    Dose
    200mg, at bedtime
    Outcome
    return to school full time and reached normal functioning
    Effect
    better (not tested)
    Risk of bias
    case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I

Side effects

Side effects studies reported4 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Dizziness1 study
Fatigue1 study
Nausea or stomach upset1 study
Worse symptoms or a flare1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    200 to 900 mg at the start

  2. 2Raise

    Raised step by step in 1 of 3 studies

  3. 3Top dose

    Most often 200 mg (1 of 3 studies)

Doses across 3 studies

200 to 300 mg. One study of 44 people went up to 3600 mg.

Each study’s dose, as printed

All papers

  1. Efficacy of Gabapentin For Post-COVID-19 Olfactory Dysfunction: The GRACE Randomized Clinical Trial.2023 · randomised trial · 68 randomised · 44 analysed
    Summary

    This double-blinded, placebo-controlled pilot randomized clinical trial tested oral gabapentin for smell loss after COVID-19 in adults with at least 3 months of olfactory dysfunction, recruited through the Washington University School of Medicine Volunteers for Health Research Participant Registry and the Otolaryngology Research Participant Registry, with all assessments completed online. Sixty-eight participants were enrolled: 34 randomized to gabapentin and 34 to placebo, titrated to a maximum dose of 3600 mg/d, maintained for an 8-week fixed-dose (FD) phase, then tapered, with follow-up 4 weeks after taper; study duration up to 18 weeks. The primary outcome was response rate on the Clinical Global Impression of Improvement after the FD phase. Of the 18 participants in the gabapentin group, 8 (44.4%) were responders and of the 26 in the placebo group, 12 (46.2%) reported response (percent difference, −1.7%; 95% CI, −31.6 to 28.2). A total of 44 participants completed the FD period and 20 (45.4%) reported response. Four weeks after taper, 7 of 16 in the gabapentin group and 12 of 25 in the placebo group were responders. Mixed-model analysis showed no significant difference in UPSIT, NASAL-7, and ODOR scores between groups. Adverse events included fatigue (10 gabapentin, 11 placebo), dizziness (6 vs no participants), weight gain (5 vs no participants) and brain fog (6 vs 2); no serious adverse events were noted in either group, and 48% of participants were unable to tolerate the maximum dose of 3600 mg and had their dosage reduced.

  2. Patient-reported treatment outcomes in ME/CFS and long COVID.2025 · no comparison group · 5,451 in the study · 3,925 with outcome data
  3. Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
    Summary

    This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.

  4. 1171 Hypersomnia Secondary to Long Covid2024 · case report · 1 in the study
  5. Use of Neuromodulation to Treat Post-COVID Neuropathic Pain: A Case Report.2024 · case report · 1 in the study
    Summary

    This case report describes one 27-year-old man with bilateral upper-extremity neuropathic pain that began with a severe COVID-19 infection about 2 years before presentation. There was no comparison group; reports are before and after treatment in this one patient. He had occupational therapy and trials of amlodipine, sildenafil, gabapentin, duloxetine, and low-dos naltrexone 4.5 mg daily, and a stellate ganglion block, which he said gave no noticeable benefit. He then received a Nevro device with cervical lead placement. A single lead trial with the tip at the C2/C3 interspace gave excellent relief, with a >70% decrease in baseline pain, improved functionality, and increased ability to participate in physical therapy. At implant, two leads were placed, one at C2/C3 and one staggered at C3. More than 6 months after surgery, he reported a 50% improvement in baseline pain and improved functionality, including lifting weights and repetitive motions; he recovered more quickly from pain flares and was quite pleased with the device. Gabapentin seemed most helpful, but he had dosis-limiting side effects, including lethargy. No harms were reported for the device. The authors state limits of case reports: lack of generalisability, inability to establish cause and effect, retrospective design, and potential for overinterpretation.

  6. Severe eosinophilic colitis caused by neuropathic agents in a patient with chronic fatigue syndrome and functional abdominal pain: case report and review of the literature.2018 · case report · 1 in the study
    Summary

    This case report describes one 18-year-old girl with severe chronic fatigue syndrome/myalgic encephalopathy and functional abdominal pain, admitted as an inpatient for enteral feeding and physical rehabilitation. Gabapentin was started for severe musculoskeletal pain and hyperalgesia; it was stopped after one and a half months. Later pregabalin was added by another team. There was no comparison group. The report describes symptoms, eosinophil counts, faecal calprotectin, imaging, colonoscopy and biopsies. Within five days of gabapentin the patient developed severe right iliac fossa pain and explosive, malodorous diarrhoea; eosinophil count peaked at 1.93 x 109/L (0.0-0.4). Small bowel ultrasound showed resolution of inflammation weeks after gabapentin cessation. Pregabalin again exacerbated abdominal pain and diarrhoea recurred; faecal calprotectin was raised again to 176 μg/g and biopsies confirmed eosinophilic colitis. The report records gabapentin stopped and pregabalin followed by recurrent symptoms as withdrawals due to harms. Symptoms improved upon discontinuation of the drugs and steroid administration. The authors state that EC is exceptionally rare and its mechanism is unclear.

  7. Late onset and persistent parosmia and dysgeusia as neurosensorial complication by the SARS virus COV 2.2023 · combination: given with other treatments · 1 in the study
    Summary

    This case report described one 25-year-old female with delayed and prolonged post-COVID parosmia and dysgeusia; the authors presented their treatment experience. There was no comparison group. Treatments included prednisone 0.5 mg/kg for 8 days, nasal irrigation with saline solution three times a day for 10 days plus Mupirocin for 10 days, Gabapentin 300 mg orally every 8 hours for 1 month, Escitalopram 5 mg daily, multivitamins, and olfactory rehabilitation. A transfusion of 50 million mesenchymal stem cells of endometrial origin showed no evidence of improvement even 8 weeks after it. The first COVID-19 vaccine dose was followed by an improvement of 25% of the parosmia and dysgeusia in the 7 days after application. After the second dose, an olfactory test found 40%, compared with 2 of 16 odors (12%) identified earlier. The report described mild improvement with prednisone, gabapentin, nasal irrigations and olfactory rehabilitation, greater after the second vaccine dose; improvement in depression but minimal improvement in parosmia and dysgeusia. Harms and withdrawals were not reported. Follow-up was 12 months after suffering the condition, when parosmia and dysgeusia still persisted.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime